LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, announced that management has commenced preliminary due diligence and strategic planning for the company's expansion into Colombia. The initial phase includes evaluating corporate, regulatory, legal, operational, and commercial requirements for establishing a Colombian operating subsidiary and deploying the company's digital healthcare platform.
Management believes Colombia represents an attractive long-term market as LataMed AI advances its broader Latin American expansion strategy. The ongoing review is expected to assess corporate formation, regulatory compliance, healthcare technology implementation, strategic partnerships, and local operational infrastructure necessary to support future operations.
The evaluation is intended to build upon LataMed's growing healthcare ecosystem by identifying opportunities to expand access to telehealth infrastructure, healthcare coordination technologies, digital healthcare services, insurance accessibility initiatives, pharmacy integration opportunities, payment accessibility solutions, and artificial intelligence-driven healthcare technologies in additional Latin American markets.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: “Colombia represents an important strategic opportunity as we continue executing our long-term vision of building an integrated digital healthcare ecosystem across Latin America. While we remain in the early stages of evaluating market entry requirements, we believe it is important to establish the proper legal, operational, and strategic foundation before expanding into new jurisdictions.”
The company emphasized that the Colombia expansion initiative remains in the preliminary planning and due diligence stage. Management intends to complete the required corporate, regulatory, and operational review before proceeding with establishing a Colombian subsidiary and expects to provide additional updates as material developments occur.
For additional information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
